Agalsidase alfa, agalsidase beta – July 2026

Solution for I.V. injection 3.5 mg in 3.5 mL vial
Powder for I.V. infusion, 5 mg vial
Powder for I.V. infusion, 35 mg vial

  • Brand names:
    • Replagal®
    • Fabrazyme®
  • Pharmaceutical Company:
    • TAKEDA PHARMACEUTICALS AUSTRALIA PTY LTD, SANOFI AUSTRALIA AND NEW ZEALAND
  • Condition/Indication: Fabry disease
  • Meeting Date: July 2026

Last updated
13 November 2026